Inbec治疗什么病？

What diseases does Suimeikai (Dotiabalamid Tablets, Inbec) treat? Suimeikai (Domitabalamid Tablets, Inbec) is an ideal drug for the treatment of AIDS patients. Many AIDS patients choose Suimeike (Domitabalamid Tablets, Inbec) for treatment. Suimeike (dolute abalamide tablets, Inbec) is a three-in-one compound drug for the treatment of adults and adolescents over 12 years old (weight at least 40kg) infected with human immunodeficiency virus (HIV). This is also the only three-in-one compound drug currently containing dolutegravir (DTG). It integrates treatment drugs for different stages of viral infection into the same tablet. Patients only need to take one drug to achieve the effect of combined medication.

For adults and adolescents, the recommended dose of Trimax (Inbec) is one tablet, once daily. Adults or adolescents who weigh less than 40 kg should not be given Trimax (Inbec) because Trimax (Inbec) is a fixed-dose tablet and cannot be reduced.

Trimax (dolutegravir, Inbec) is a fixed-dose tablet and should not be used in patients who require dose adjustments. If one of the active ingredients needs to be discontinued or a dose adjustment is required, separate formulations of dolutegravir, abacavir or lamivudine can be used. In these cases, physicians should refer to the respective product information for these medicines. 

If the patient misses a dose of Trimax (Inbec) and it is more than 4 hours before the next dose, he should take Trimax (Inbec) as soon as possible. If the next dose is less than 4 hours away, patients should not take the missed dose and simply resume their usual dosing schedule. 

Suimeikai (Domitabalamid Tablets, Inbec) has the characteristics of good efficacy and few side effects in treating HIV. Common side effects include nausea (12%), insomnia (7%), dizziness (6%) and headache (6%). Patients with abacavir hypersensitivity often experience symptoms such as nausea, vomiting, diarrhea, fever, drowsiness, and rash when using Suimeike (Dolutea Abalamib Tablets, Inbec).